Webinar: Shattering preconceptions – Can Cannabis be a force for good?
Shattering preconceptions, can Cannabis be a force for good?
Cannabis has become one of the most socially disruptive phenomena of our time. In the sector, it is the medical opportunity that has caught the attention of most investors. UK-based company GW Pharma’s trail-blazing ascent, built on their FDA approved drug, Epidiolex, has offered scientific evidence for cannabis’ medical potential. It has convinced investors that this is a market that they need to be paying closer attention to. Further drug development is now underway. Not just at GW Pharma, but at a host of other pharmaceutical cannabis companies. Companies are looking to address everything from Crohn’s disease, IBD, dyspepsia and spasticity.
As further therapeutic properties of cannabinoids are uncovered, investors will be looking for ways to participate in the growth. At the same time, investors have the chance to invest today in getting these new formulations into the hands of people who need it the most; to be true agents of change. Cannabis-derived already exist for conditions like neuropathic pain (Cesamet), anorexia (Marinol and Syndros) and seizures (Epidiolex). But as we move forward, this market will get bigger from there. It is estimated that the global medical cannabis market could be worth as much as USD 148.35 billion (Imarc Group, 2019) by 2026. Here at Rize ETF, we believe this figure to be conservative.
In this webinar, we unpacked the global conversation around medical cannabis. We shared our perspectives on the market’s growth drivers, and why we believe investors have the chance to invest in something that will create a positive impact. Finally, we looked at medical cannabis stocks through the growth and diversification, and discuss how such a basket can add value to an investor’s portfolio.
Recorded on July 8th 2020.
FLWR: The Rize Medical Cannabis and Life Sciences UCITS ETF seeks to track the Foxberry Medical Cannabis & Life Sciences Index. The objective of the Index is to provide exposure to companies involved in the global medical cannabis and cannabis-related life sciences sectors, with a focus on companies in the biotechnology/pharma and hemp and cannabidiol (CBD) sectors. The Index excludes companies that are considered to be either non-compliant with state and federal laws in the countries in which they operate and/or directly involved in the production and/or distribution of cannabis and/or cannabis-derived products containing more than hemp-defined levels of tetrahydrocannabinol (THC) for the recreational consumer market.
Capital at Risk Warning: An investment in the Fund(s) involves risks, including illiquidity, lack of dividends, loss of investment and dilution, and it should be done only as part of a diversified portfolio. The Funds may be registered or otherwise approved for distribution to the public in one or more European jurisdictions. Investors should continue to consider the terms of investment in any Fund (or Share Class thereof) carefully and seek professional investment advice before taking any decision to invest in such Fund (or Share Class thereof).